EN
抗体药类似物
Research Grade Ogalvibart
All
  • CatalogTD-VK565296
  • ClonalitymAb
  • Application Research Grade Biosimilar
  • SynonymsBMS986414,BMS-986414,BMS986414,C-135-LS,CAS:2599039-60-6
  • 规格
    1mg
  • 价格
    ¥询价
定制服务咨询

Research Grade Ogalvibart


Catalog No. TD-VK565296
Species reactivity SARS-CoV-2 (2019-nCoV)
Applications Research Grade Biosimilar
Host species Human
Isotype IgG1, kappa
Expression system Mammalian Cells
Clonality Monoclonal
Target Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, Spike protein S2, Spike protein S2', S, 2, Receptor-Binding Domain, RBD
Endotoxin level Please contact the lab for this information.
Purity >95% purity as determined by SDS-PAGE.
Purification Protein A/G, purified from cell culture supernatant.
Accession P0DTC2-2
Form Liquid
Storage buffer 0.01M PBS,pH7.4.
Stability and Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names BMS986414,BMS-986414,BMS986414,C-135-LS,CAS:2599039-60-6
Background Ogalvibart (C-135-LS) is a human anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model.
Note For research use only. Not for use in clinical or therapeutic applications.